JOINT FILING AGREEMENT
Exhibit 99.2
The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Mirum Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(d) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.
This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
Date: January 27, 2021
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||||
| By | /s/ Xxxxxxxxx Xxxxxxxx | |||||||
| Name: | Xxxxxxxxx Xxxxxxxx | |||||||
| Title: | Corporate Officer, Global General Counsel | |||||||
| TAKEDA PHARMACEUTICALS U.S.A, INC. | ||||||||
| By | /s/ Xxxx Xxxxxxxx | |||||||
| Name: | Xxxx Xxxxxxxx | |||||||
| Title: | Assistant Secretary | |||||||
| SHIRE INTERNATIONAL GMBH IN LIQUIDATION | ||||||||
| By | /s/ Xxxxxxx Xxxxxxxxxx | |||||||
| Name: | Xxxxxxx Xxxxxxxxxx | |||||||
| Title: | Liquidator | |||||||
